A simple method to design antibodies aimed at combating Alzheimer's disease has been developed by scientists.
Antibodies are large proteins produced by the immune system to combat infection and disease. They are comprised of a large Y-shaped protein topped with small peptide loops. These loops bind to harmful invaders in the body, such as a viruses or bacteria.
Alzheimers Disease
Alzheimer''s disease is a progressive neurodegenerative disease affecting memory and thinking and making the person increasingly dependent on others.
Advertisement
Once an antibody is bound to its target, the immune system sends cells to destroy the invader. Finding the right antibody can determine the difference between death and recovery.
When trying to design an antibody, the arrangement and sequence of the antibody loops is of utmost importance. Only a very specific combination of antibody loops will bind to and neutralize each target.
![Quiz On Alzheimer’s Disease]( "Quiz On Alzheimer’s Disease")
Alzheimer's disease (AD) is the most common form of dementia. Participate in this quiz to find out how much you know about this debilitating disease.
With billions of different possible loop arrangements and sequences, it is seemingly impossible to predict which antibody loops will bind to a specific target molecule.
The new antibody design process was used to create antibodies that target a devastating molecule in the body - the Alzheimer's protein.
The research, led by Assistant Professor of Chemical and Biological Engineering Peter Tessier, uses the same molecular interactions that cause the Alzheimer's proteins to stick together and form the toxic particles that are a hallmark of the disease.
"We are actually exploiting the same protein interactions that cause the disease in the brain to mediate binding of antibodies to toxic Alzheimer's protein particles," Tessier said.
Alzheimer's disease is due to a specific protein, the Alzheimer's protein, sticking together to form protein particles. These particles then damage the normal, healthy functions of the brain. The formation of similar toxic protein particles is central to diseases such as Parkinson's and mad cow disease.
Importantly, the new Alzheimer's antibodies developed by Tessier and his colleagues only latched on to the harmful clumped proteins and not the harmless monomers or single peptides that are not associated with disease.
The study has been published in the Early Edition of the journal Proceedings of the National Academy of Sciences (PNAS).
Source: ANI
Quiz On Alzheimer’s Disease
Alzheimer's disease (AD) is the most common form of dementia. Participate in this quiz to find out how much you know about this debilitating disease.
Advertisement
With billions of different possible loop arrangements and sequences, it is seemingly impossible to predict which antibody loops will bind to a specific target molecule.
The new antibody design process was used to create antibodies that target a devastating molecule in the body - the Alzheimer's protein.
The research, led by Assistant Professor of Chemical and Biological Engineering Peter Tessier, uses the same molecular interactions that cause the Alzheimer's proteins to stick together and form the toxic particles that are a hallmark of the disease.
"We are actually exploiting the same protein interactions that cause the disease in the brain to mediate binding of antibodies to toxic Alzheimer's protein particles," Tessier said.
Alzheimer's disease is due to a specific protein, the Alzheimer's protein, sticking together to form protein particles. These particles then damage the normal, healthy functions of the brain. The formation of similar toxic protein particles is central to diseases such as Parkinson's and mad cow disease.
Importantly, the new Alzheimer's antibodies developed by Tessier and his colleagues only latched on to the harmful clumped proteins and not the harmless monomers or single peptides that are not associated with disease.
The study has been published in the Early Edition of the journal Proceedings of the National Academy of Sciences (PNAS).
Source: ANI
Caring for Alzheimers disease patients
Alzheimer's disease is a complex brain disorder that triggers the most common form of dementia. The slide show will show how patients need support and care as dementia progresses.
Advertisement
 Medicines Meant to Treat Alzheimers Found to be Good for Victims of DementiaCholinesterase inhibitors, that help victims of Alzheimer's disease can also assist in the management of behavioural and psychological symptoms of dementia, a new study has shown. | Advertisement
|
Advertisement
Recommended Reading
Latest Research News
Does omega-3 help Alzheimer's patients? A new form of omega-3 helped restore specific markers of eye health in mice bred with aspects of early-onset Alzheimer's disease.
Drugs used to inhibit the physiological responses for allergic reactions lessen osteoarthritis risk, revealed research.
The International Space Station will be used to carry out experiments seeking to improve understanding of incurable child brain tumors and the muscle aging process.
How many people in the UK have misophonia? In a representative sample study, most people had at least some irritation upon hearing trigger sounds.
Routine eye-checkups and mass screenings enable early diagnosis and treatment of glaucoma. Late-stage glaucoma diagnosis leads to blindness.